New Botox Competitor to Debut Next Month
Cosmetic use of Xeomin (Merz Pharmaceuticals] will be considered off-label use as of its initial US launch in September 2010. The drug was approved by the FDA in August 2010 only for treating neuromuscular conditions, such as cervical dystonia and blepharospasm, and is not yet approved to treat dynamic wrinkles between the brows and on the forehead.
Although Botox and Dysport are both approved for cosmetic use in addition to therapeutic use, Xeomin is expected to compete directly with the two botulinum toxin type A wrinkle-relaxing injectables.
Xeomin, Dysport, and Botox are each composed of similar, yet slightly different formulations of the botulinum toxin type A neurotoxin. The formulation in Xeomin (incobotulinumtoxinA) is particularly unique because it is free of complexing proteins, which may give Xeomin an advantage over Botox and Dysport in treating neuromuscular conditions, since the higher doses necessary can be given without resulting in antibody formation.
Xeomin’s lack of complexing proteins is not seen as a potential advantage over Dysport or Botox when it comes to cosmetic use. However, as the doses used to smooth forehead wrinkles and frown lines is so low, there is no noticeable difference. In fact, some physicians are concerned that it may be more difficult to control spreading or migration of Xeomin, which may lead to muscle relaxation that causes droopy eyebrows and other undesirable results.
Essentially, the effects of Xeomin injections for wrinkle reduction are anticipated to closely mirror the effects of Botox injections. The unit measurements of the two products are even expected to be about the same, although Botox is distributed in 100-unit vials, and Xeomin will be distributed in 50-unit and 100-unit vials.
The only other notable difference is that Xeomin will not require refrigeration prior to reconstitution as Botox and Dysport do, which is a convenience to physicians that likely will not affect consumers.
The lack of fluctuation in Botox prices after Dysport, its first competitor, was launched in April 2009 suggests that the introduction of Xeomin to the US market will not cause a decrease in the price of wrinkle-relaxing injections.
Although Botox and Dysport are both approved for cosmetic use in addition to therapeutic use, Xeomin is expected to compete directly with the two botulinum toxin type A wrinkle-relaxing injectables.
Xeomin, Dysport, and Botox are each composed of similar, yet slightly different formulations of the botulinum toxin type A neurotoxin. The formulation in Xeomin (incobotulinumtoxinA) is particularly unique because it is free of complexing proteins, which may give Xeomin an advantage over Botox and Dysport in treating neuromuscular conditions, since the higher doses necessary can be given without resulting in antibody formation.
Xeomin’s lack of complexing proteins is not seen as a potential advantage over Dysport or Botox when it comes to cosmetic use. However, as the doses used to smooth forehead wrinkles and frown lines is so low, there is no noticeable difference. In fact, some physicians are concerned that it may be more difficult to control spreading or migration of Xeomin, which may lead to muscle relaxation that causes droopy eyebrows and other undesirable results.
Essentially, the effects of Xeomin injections for wrinkle reduction are anticipated to closely mirror the effects of Botox injections. The unit measurements of the two products are even expected to be about the same, although Botox is distributed in 100-unit vials, and Xeomin will be distributed in 50-unit and 100-unit vials.
The only other notable difference is that Xeomin will not require refrigeration prior to reconstitution as Botox and Dysport do, which is a convenience to physicians that likely will not affect consumers.
The lack of fluctuation in Botox prices after Dysport, its first competitor, was launched in April 2009 suggests that the introduction of Xeomin to the US market will not cause a decrease in the price of wrinkle-relaxing injections.
Very interesting & professional site. You done great work. el faro el salvador education thesis topic keats ode on melancholy curvature spinal gift certificate sexual arousal tibia xx.pl black history thematic unit old seven mile bridge.
ReplyDeleteplastic surgeon baton rouge